[[center]Vigabatrin REMS Program for Prescribers]
[shadow]
[width-75]
- The US Food and Drug Administration (FDA) has approved a single shared system Risk Evaluation and Mitigation Strategy (REMS) for all vigabatrin products, called the Vigabatrin REMS Program. The Vigabatrin REMS Program is required by the FDA to ensure informed risk-benefit decisions before initiating treatment, and to ensure appropriate use of vigabatrin while patients are treated. By clicking on the link below, prescribers will be taken to the website that now manages the process and contains the required vigabatrin REMS forms
- Branded Sabril ® (vigabatrin) is still available. Prescribers can continue to submit the Sabril Prescription Form through the SHAREPlus program
[[center,button]Click here to proceed to www.vigabatrinREMS.com]
[[center]Sabril Prescription Form for Prescribers]
[width-75]
- The optional Sabril Prescription Form will continue to be available for physicians who choose to submit a Sabril prescription through Lundbeck’s SHAREPlus program. When completing the Sabril Prescription Form, indicate “Dispense as written (DAW)” or follow your state's instructions for indicating branded vs. generic product. Fax the completed form to SHAREPlus at 1-877-742-1002
- Alternatively, if you do not want to submit your Sabril prescription through SHAREPlus, you can send it directly to a certified pharmacy found on the Vigabatrin REMS website. Indicate “Dispense as written (DAW)” or follow your state's instructions for indicating branded vs. generic product
[[button]Download the Sabril Prescription Form ]
